MindFrame LP Devices Receive CE Mark Approval for Treatment of Patients Experiencing Ischemic Stroke

First and only devices that can be deployed through microcatheters as small as 10/14 offer improved access and increased aspiration

IRVINE, Calif.--()--MindFrame Inc. today announces receiving CE mark approval for the MindFrame Capture LP™ and MindFrame Flow LP™ devices. Part of the comprehensive portfolio of MindFrame Therapy Solutions™, these low profile devices can be deployed through a smaller microcatheter to improve access through tortuous vessel anatomies. MindFrame devices are expressly engineered to treat patients suffering from ischemic stroke through microcatheter-based flow restoration and clot extraction, allowing neurointerventionalists to achieve successful procedural and clinical outcomes for patients. Rapid blood flow restoration and removal of the clot is essential to prevent the irreversible deterioration of brain function in patients suffering from acute ischemic stroke.

“This unique device technology offers improved ability to access thrombus through tortuous blood vessel anatomies, allowing for rapid perfusion and thrombus retrieval,” said Tommy Andersson, MD, PhD, Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden. “The MindFrame LP devices allow me to restore blood flow and preserve brain function for my patients, providing the potential of being the standard in ischemic stroke treatment.”

MindFrame Capture LP and MindFrame Flow LP are compatible with any microcatheter 10/14 or greater. With the MindFrame LP devices, clinicians can expect the additional benefit of increased thrombus aspiration when needed, both locally and proximally, as a result of the reduced microcatheter size. The devices offer improved tensile strength and kink resistance for device durability, as well as enhanced trackability for precise placement and control.

“Receiving the CE mark approval for the MindFrame LP devices is a significant accomplishment,” said Kenneth Charhut, president and CEO of MindFrame Inc. “Through our rapid development of these advanced devices, MindFrame Capture LP and MindFrame Flow LP represent the next generation in device technology. MindFrame is committed to developing leading-edge devices that provide improved procedural and clinical outcomes for clinicians and their patients.”

MindFrame Capture LP and MindFrame Flow LP devices are not approved for sale in the United States.

For more information about the breakthrough MindFrame Capture LP and MindFrame Flow LP devices, visit www.MindFrameInc.com.

About MindFrame Inc.

MindFrame Inc. is a pioneer in developing optimized technologies for patients experiencing ischemic stroke. The breakthrough MindFrame Therapy Solutions portfolio comprises some of the most advanced device design technology that delivers exceptional rapid flow restoration and clot extraction intended to help clinicians provide improved clinical outcomes for their patients. For more information about these state-of-the-art technologies, visit www.MindFrameInc.com.

Contacts

DevicePharm
Shannon Jacobs, 949-271-1180
shannonj@devicepharm.com

Release Summary

MindFrame LP is the first and only CE approved device that can be deployed through microcatheters as small as 10/14, offering improved access for neurointerventionalists treating ischemic stroke.

Sharing

Contacts

DevicePharm
Shannon Jacobs, 949-271-1180
shannonj@devicepharm.com